Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

Abstract Background N8‐GP (turoctocog alfa pegol; Esperoct) is a glycoPEGylated human recombinant factor VIII (FVIII). Objectives Pathfinder8 (NCT01480180) was a phase 3, multinational, open‐label, nonrandomized trial to investigate the long‐term safety and efficacy of N8‐GP in people of all ages wi...

Full description

Bibliographic Details
Main Authors: Steven R. Lentz, Kaan Kavakli, Robert Klamroth, Mudi Misgav, Azusa Nagao, Alberto Tosetto, Pernille Juul Jørgensen, Marek Zak, Laszlo Nemes
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
factor VIII
hemophilia A
prophylaxis
safety
turoctocog alfa pegol
Online Access:https://doi.org/10.1002/rth2.12674

Internet

https://doi.org/10.1002/rth2.12674

Similar Items